DK2197900T3 - Mutante dobbeltringsluttede receptorpeptider, der inhiberer beta1-adrenoreceptorantistoffer - Google Patents

Mutante dobbeltringsluttede receptorpeptider, der inhiberer beta1-adrenoreceptorantistoffer

Info

Publication number
DK2197900T3
DK2197900T3 DK08801676.1T DK08801676T DK2197900T3 DK 2197900 T3 DK2197900 T3 DK 2197900T3 DK 08801676 T DK08801676 T DK 08801676T DK 2197900 T3 DK2197900 T3 DK 2197900T3
Authority
DK
Denmark
Prior art keywords
beta1
adrenoreceptor
antibodies
inhibit
receptor peptides
Prior art date
Application number
DK08801676.1T
Other languages
English (en)
Inventor
Roland Jahns
Valerie Jahns
Martin Lohse
Viacheslav Nikolaev
Original Assignee
Univ Wuerzburg J Maximilians
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Wuerzburg J Maximilians filed Critical Univ Wuerzburg J Maximilians
Application granted granted Critical
Publication of DK2197900T3 publication Critical patent/DK2197900T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
DK08801676.1T 2007-08-24 2008-08-22 Mutante dobbeltringsluttede receptorpeptider, der inhiberer beta1-adrenoreceptorantistoffer DK2197900T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07016637 2007-08-24
PCT/EP2008/006932 WO2009027063A2 (en) 2007-08-24 2008-08-22 MUTANT DOUBLE CYCLIZED RECEPTOR PEPTIDES INHIBITING β1-ADRENOCEPTOR ANTIBODIES

Publications (1)

Publication Number Publication Date
DK2197900T3 true DK2197900T3 (da) 2012-10-22

Family

ID=40130559

Family Applications (1)

Application Number Title Priority Date Filing Date
DK08801676.1T DK2197900T3 (da) 2007-08-24 2008-08-22 Mutante dobbeltringsluttede receptorpeptider, der inhiberer beta1-adrenoreceptorantistoffer

Country Status (14)

Country Link
US (1) US9062095B2 (da)
EP (3) EP2497777A3 (da)
JP (3) JP5248610B2 (da)
CN (2) CN101835793B (da)
AU (1) AU2008291296B2 (da)
CA (1) CA2697108C (da)
DK (1) DK2197900T3 (da)
ES (1) ES2391358T3 (da)
HK (1) HK1176363A1 (da)
HR (1) HRP20120827T1 (da)
PL (1) PL2197900T3 (da)
PT (1) PT2197900E (da)
SI (1) SI2197900T1 (da)
WO (1) WO2009027063A2 (da)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2697108C (en) * 2007-08-24 2018-05-22 Julius-Maximilians-Universitaet Wuerzburg Mutant double cyclized receptor peptides inhibiting .beta.1-adrenoceptor antibodies
BRPI1007007A2 (pt) * 2009-01-27 2016-03-22 Julius Maximilians Universität Würzburg peptídeos cíclico, molécula de ácido nucleico, vetor, célula hospedeira, método para produção de um peptídeo cíclico, composição farmacêutica, método para detecção de anticorpos contra um b-ar (em uma amostra)
DE102010018878B4 (de) 2009-04-30 2013-09-26 Julius-Maximilians-Universität Würzburg Neue Zell-Linie zur Fluoreszenz-basierten Detektion von funktionell aktiven Antikörpern und Autoantikörpern gegen den Beta1-adrenergen Rezeptor
EP2402016A1 (en) * 2010-06-29 2012-01-04 Charité - Universitätsmedizin Berlin Aptamers that inhibit interaction between antibody and 1st or 2nd extracellular loop of human beta-1-adrenergic receptor
MX2013014475A (es) 2011-06-10 2014-05-27 Corimmun Gmbh COMPUESTOS DE ENLACE A ß1-ADRENORECEPTOR HUMANO (ß-AR) Y SU USO EN LA MEDICION DE ANTICUERPOS AUTO-ANTI-ß1-AR.
ES2652136T3 (es) 2012-02-16 2018-01-31 Atyr Pharma, Inc. Histidil-tRNA sintetasas para tratar enfermedades autoinmunitarias e inflamatorias
EP2970921B1 (en) 2013-03-15 2018-09-19 aTyr Pharma, Inc. Histidyl-trna synthetase-fc conjugates
WO2015022953A1 (ja) * 2013-08-14 2015-02-19 株式会社新日本科学 血液脳関門障害改善剤
WO2018195338A1 (en) 2017-04-20 2018-10-25 Atyr Pharma, Inc. Compositions and methods for treating lung inflammation
CN108218963B (zh) * 2018-01-19 2020-10-13 首都医科大学 一种环肽及其制备方法和用途
CA3130446A1 (en) * 2019-03-14 2020-09-17 Genentech, Inc. Treatment of cancer with her2xcd3 bispecific antibodies in combination with anti-her2 mab
US11986536B2 (en) 2019-03-23 2024-05-21 Ablevia Biotech Gmbh Compound for the sequestration of undesirable antibodies in a patient
EP3715374A1 (en) 2019-03-23 2020-09-30 Ablevia biotech GmbH Compound for the sequestration of undesirable antibodies in a patient
JP2023542389A (ja) * 2020-09-23 2023-10-06 アブレヴィア バイオテック ゲーエムベーハー 自己抗体で媒介される状態の予防又は治療のための化合物
CN112266330B (zh) * 2020-10-15 2023-02-24 长沙博源医疗科技有限公司 一种甲氧基肾上腺素衍生物、免疫原、抗甲氧基肾上腺素特异性抗体及其制备方法与应用
WO2023028590A1 (en) * 2021-08-27 2023-03-02 Yale University Molecular degraders of extracellular proteins
JP2023117892A (ja) * 2022-02-14 2023-08-24 公益財団法人 鷹揚郷 ヘプシジン結合ペプチド

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4711955A (en) 1981-04-17 1987-12-08 Yale University Modified nucleotides and methods of preparing and using same
CA1223831A (en) 1982-06-23 1987-07-07 Dean Engelhardt Modified nucleotides, methods of preparing and utilizing and compositions containing the same
US4880635B1 (en) 1984-08-08 1996-07-02 Liposome Company Dehydrated liposomes
US5792608A (en) 1991-12-12 1998-08-11 Gilead Sciences, Inc. Nuclease stable and binding competent oligomers and methods for their use
US5525711A (en) 1994-05-18 1996-06-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Pteridine nucleotide analogs as fluorescent DNA probes
WO2001034208A1 (en) * 1999-11-05 2001-05-17 The Regents Of The University Of California Techniques and compositions for treating cardiovascular disease by in vivo gene delivery
DE50013435D1 (de) * 1999-09-21 2006-10-19 Fresenius Medical Care Affina Peptide gegen dcm hervorrufende autoantikörper
US20040001827A1 (en) * 2002-06-28 2004-01-01 Dennis Mark S. Serum albumin binding peptides for tumor targeting
JP4541490B2 (ja) * 2000-04-07 2010-09-08 株式会社カネカ 拡張型心筋症用吸着体
AU2001259195A1 (en) * 2000-04-28 2001-11-12 Glaxo Group Limited Compounds having affinity for the vascular endothelial growth factor receptor-2 (vegfr-2) and associated uses
CN1988914A (zh) * 2001-08-23 2007-06-27 西兰制药公司 胞间通讯易化化合物的新医学用途
JP2005521733A (ja) * 2002-03-26 2005-07-21 ダイアックス、コープ フィブリノーゲン結合部分
US20080206264A1 (en) * 2003-02-04 2008-08-28 New York University Constrained Hiv V3 Loop Peptides as Novel Immunogens and Receptor Antagonists
EP1536020A1 (en) 2003-11-26 2005-06-01 Bayerische Julius-Maximilians-Universität Würzburg Means and methods for optical determination of cAMP in vitro and in vivo
AU2006228664B2 (en) * 2005-03-31 2012-11-01 Julius-Maximilians-Universitat Wurzburg Means for the inhibition of anti-beta1-adrenergic receptor antibodies
CA2697108C (en) * 2007-08-24 2018-05-22 Julius-Maximilians-Universitaet Wuerzburg Mutant double cyclized receptor peptides inhibiting .beta.1-adrenoceptor antibodies

Also Published As

Publication number Publication date
US20100209445A1 (en) 2010-08-19
EP2197900B9 (en) 2013-01-09
US9062095B2 (en) 2015-06-23
JP2013138679A (ja) 2013-07-18
HK1176363A1 (en) 2013-07-26
SI2197900T1 (sl) 2012-11-30
JP5248610B2 (ja) 2013-07-31
EP2197900A2 (en) 2010-06-23
PL2197900T3 (pl) 2012-12-31
WO2009027063A2 (en) 2009-03-05
CN103992406A (zh) 2014-08-20
ES2391358T3 (es) 2012-11-23
AU2008291296B2 (en) 2014-02-06
EP2197900B1 (en) 2012-08-01
EP2497777A2 (en) 2012-09-12
EP2559698A3 (en) 2013-03-06
EP2559698B1 (en) 2014-11-12
CN101835793A (zh) 2010-09-15
JP2013176369A (ja) 2013-09-09
EP2497777A3 (en) 2012-10-10
CA2697108A1 (en) 2009-03-05
AU2008291296A1 (en) 2009-03-05
HRP20120827T1 (hr) 2012-11-30
CN101835793B (zh) 2014-04-23
JP2010536356A (ja) 2010-12-02
EP2559698A2 (en) 2013-02-20
PT2197900E (pt) 2012-10-24
CA2697108C (en) 2018-05-22
WO2009027063A3 (en) 2009-07-23

Similar Documents

Publication Publication Date Title
DK2197900T3 (da) Mutante dobbeltringsluttede receptorpeptider, der inhiberer beta1-adrenoreceptorantistoffer
CY2019004I1 (el) Τροποποιημενα αντισωματα αντι-ιl-23ρ19
BRPI0912260A2 (pt) tonalizador.
BRPI0807991A2 (pt) Anticorpos anti-il-23r elaborados.
ATE509022T1 (de) Nikotin-acetylcholin-rezeptorsubtyp-selektive diazabicycloalkanamide
BRPI0813235A2 (pt) Combinação anti-helmíntica.
AP2011005719A0 (en) Anti-IGF antibodies.
BRPI0819165A2 (pt) Anticorpos anti-vegf
IL204536A0 (en) Anti - il -6 receptor antibody
BRPI0906877A2 (pt) Anticorpos anti-trkb aperfeiçoados
ATE513831T1 (de) Pyridinä3,4-büpyrazinone
ITMI20071002A1 (it) Manufatto per edilizia.
BRPI0817427A2 (pt) Anticorpo anti-bst2
ATE502016T1 (de) Triazolo-ä1,5-aü-chinoline als adenosin-a3- rezeptorliganden
IT1396642B1 (it) Statore.
BRPI0815055A2 (pt) aparelho de ciclone.
FR2913338B1 (fr) Composition de rehydratation.
FI7604U1 (fi) Tuntoelin
NL2002217A1 (nl) Mat.
FR2914669B1 (fr) Escalier escamotable.
BRPI0718609A2 (pt) Anticorpos modificadores de doença cancerosa.
ITMC20070246A1 (it) Sgabello monogamba.
TH99002B (th) คาร์บินอลดีริวาทีฟซึ่งมีการแทนที่
ITPA20070017A1 (it) Ciottola.
NL1033607A1 (nl) Bouwwerk.